🔎 Trials Near Me

Home › NCT04043897

Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis

RecruitingPhase 2

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Collagenous colitis (CC) or lymphocytic colitis (LC) diagnosed on colon biopsies reviewed by 2 separate pathologists
* CC will be defined histologically to be the following: thickness of the collagenous subepithelial table \>10 micrometer using an ocular micrometer, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, lack of crypt architectural distortion, and regenerative-appearing changes in the surface and/or crypt epithelium
* LC will be defined histologically to be the following: intraepithelial lymphocytes \>20 per 100 epithelial cells in the subjective area of highest lymphocyte density, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, and regenerative-appearing changes in the surface and/or crypt epithelium
* Subjects in active flare, defined as \>3 watery/loose stools per day on \>4 / 7 days over \>4 weeks in the past 3 months.

Exclusion Criteria:

\-

About the study

This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.

What is being tested

Sponsor: Eugene F Yen, MD · Participants: 10 · Started: Jun 29, 2018

Contact the study team

Official record on ClinicalTrials.gov — NCT04043897

Locations in the U.S.

IllinoisNorthShore University HealthSystem, Evanston

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.